In the BioHarmony Drug Report Database
Lybalvi (samidorphan) is a small molecule pharmaceutical. Samidorphan was first approved as Lybalvi on 2021-05-28. It is known to target delta-type opioid receptor, kappa-type opioid receptor, and mu-type opioid receptor. Lybalvi’s patents are valid until 2032-02-13 (FDA).
Image (chem structure or protein)